Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology (Q35074613)

6 August 2017

1 reference

title

Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. (English)

1 reference

6 August 2017

1 reference

3

Nanette B Silverberg

1 reference

6 August 2017

Karen M Wesson

1

1 reference

6 August 2017

Daniel S Lerner

series ordinal

2

1 reference

6 August 2017

Jeffrey M Weinberg

series ordinal

4

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Clinics in Dermatology

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

64-70

1 reference

Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

1 reference

7 January 2021

Quinupristin-dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Inhibition of protein synthesis by streptogramins and related antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Management of infections due to resistant enterococci: a review of therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Inhibition of membrane potential-dependent amino acid transport by daptomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Daptomycin: a novel agent for Gram-positive infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Once-daily dosing in dogs optimizes daptomycin safety

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900321-8

7 January 2021

10.1016/S0738-081X(02)00321-8

Identifiers

DOI

1 reference

release_wrqhtwx2bvcztowcwdbdiyqgkq

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wrqhtwx2bvcztowcwdbdiyqgkq

24 November 2022

mapped directly with Wikidata item

1 reference